Surgery Partners, Inc. (SGRY)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$14.26+0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · SGRY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain Adjusted EBITDA at or above $530 million for fiscal year 2026, excluding impact of pending divestiture.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed 2026 Adjusted EBITDA guidance of at least $530 million excluding the pending divestiture. Adjusted EBITDA was $102.3 million in 2026-Q1 and $125.2 million in 2026-Q2, showing stable performance but slightly below the implied quarterly run rate. The trajectory is delivering with reaffirmed guidance but Adjusted EBITDA is slightly below prior year periods.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding recently disclosed pending divestitur…”
“Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.”
“Initial 2026 guidance (excluding M&A) for Adjusted EBITDA of at least $530 million with revenue in the range of $3.35 billion to $3.45 billion.”
Maintain full-year 2026 revenue guidance in the range of $3.35 billion to $3.45 billion.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed 2026 revenue guidance of $3.35 billion to $3.45 billion. Quarterly revenues grew from $810.9 million in 2026-Q1 to $848.9 million in 2026-Q2, a 2.7% increase year-over-year. The trajectory is delivering consistent revenue growth aligned with guidance.
“The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion.”
“Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion.”
“Initial 2026 guidance (excluding M&A) for revenue in the range of $3.35 billion to $3.45 billion.”
Complete the divestiture of ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health to optimize portfolio.
Stated as a priority in 2 disclosures including 2026-Q2. Management announced the pending sale of Idaho Falls facilities valued at approximately $1.15 billion, with expected proceeds of about $795 million. The transaction is pending customary approvals and expected to close in coming months. This represents active progress on portfolio optimization.
“The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy.”
Maintain strong cash flow from operations and liquidity to support business operations and deleveraging.
Stated as a priority in 2 of last 3 quarters. Operating cash flow improved from $11.7 million in 2026-Q1 to $59.3 million in 2026-Q2. Cash and cash equivalents increased from $182.3 million to $216.7 million over the same period. Management links this focus to deleveraging and financial strength, showing delivering progress on liquidity.
“The Idaho Falls transaction will further strengthen our financial position, through improved cash conversion and deleveraging.”
“We continue to believe in the strong fundamentals underpinning our business. Through disciplined execution, and a continued focus on improving free cash flow and reducing leverage.”
Maintain and improve cash flow from operating activities as a key operational priority.
Over the trailing year it converted -1.39x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.